Market revenue in 2023 | USD 1.0 million |
Market revenue in 2030 | USD 15.7 million |
Growth rate | 47.9% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 90% in 2023. Horizon Databook has segmented the UK live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is one of the key countries in microbiome science and innovation in both public and private sectors. The country has growing IMT and IMMP opportunities with unique clinical research and genomic & digital capabilities.
Moreover, it is the key destination for microbiome investment and innovation. According to Innovate UK KTN, the number of live biotherapeutics products and microbiome CDMO companies is increasing in the country, such as 4D Pharma, Microbiotica, EnteroBiotix, Prokarium, and Eagle Genomics.
Among these companies, 4D Pharma has 13 biotherapeutics in development. The company has a pipeline targeted at immuno-oncology, respiratory health, neurology, gastrointestinal diseases, and autoimmune diseases. The company’s proprietary platform MicroRx helps generate its clinical trial candidates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into UK live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account